BR112019006216A2 - compostos de p2x3 e/ou p2x2/3 e métodos - Google Patents

compostos de p2x3 e/ou p2x2/3 e métodos

Info

Publication number
BR112019006216A2
BR112019006216A2 BR112019006216A BR112019006216A BR112019006216A2 BR 112019006216 A2 BR112019006216 A2 BR 112019006216A2 BR 112019006216 A BR112019006216 A BR 112019006216A BR 112019006216 A BR112019006216 A BR 112019006216A BR 112019006216 A2 BR112019006216 A2 BR 112019006216A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
useful
another embodiment
administering
Prior art date
Application number
BR112019006216A
Other languages
English (en)
Inventor
Saha Ashis
Kundu Mrinalkanti
K Thompson Scott
Nath Suvadeep
Priestley Tony
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of BR112019006216A2 publication Critical patent/BR112019006216A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

a presente refere-se a novos compostos e métodos para preparar e usar estes compostos. em uma modalidade, os compostos são da estrutura da fórmula (i), em que r1-r7 são definidos aqui. em uma outra modalidade, estes compostos são úteis no método para regular um ou ambos receptores p2x3 ou p2x2/3. em outra modalidade, estes compostos são úteis para tratar a dor em pacientes administrando um ou mais dos compostos a um paciente. em outra modalidade, estes compostos são úteis para tratar a disfunção respiratória em pacientes administrando um ou mais dos compostos a um paciente.
BR112019006216A 2016-09-30 2017-09-27 compostos de p2x3 e/ou p2x2/3 e métodos BR112019006216A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402280P 2016-09-30 2016-09-30
PCT/US2017/053660 WO2018064135A1 (en) 2016-09-30 2017-09-27 P2x3 and/or p2x2/3 compounds and methods

Publications (1)

Publication Number Publication Date
BR112019006216A2 true BR112019006216A2 (pt) 2019-06-25

Family

ID=61757797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006216A BR112019006216A2 (pt) 2016-09-30 2017-09-27 compostos de p2x3 e/ou p2x2/3 e métodos

Country Status (13)

Country Link
US (4) US10174039B2 (pt)
EP (1) EP3528813A4 (pt)
KR (1) KR20190053963A (pt)
CN (2) CN109996546B (pt)
AR (1) AR109776A1 (pt)
AU (1) AU2017335674A1 (pt)
BR (1) BR112019006216A2 (pt)
CA (1) CA3037748A1 (pt)
IL (1) IL265648A (pt)
MX (2) MX2019003710A (pt)
RU (1) RU2019112740A (pt)
TW (1) TW201827432A (pt)
WO (1) WO2018064135A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064135A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
BR112022026201A2 (pt) * 2020-06-22 2023-01-17 Corcept Therapeutics Inc Antagonistas do receptor de glicocorticoide de indazol quaternários
MX2023005805A (es) * 2020-11-27 2023-06-01 Chiesi Farm Spa Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
EP4251273A1 (en) * 2020-11-27 2023-10-04 Chiesi Farmaceutici S.p.A. Phthalazine derivatives as p2x3 inhibitors
CN114685308A (zh) * 2022-05-10 2022-07-01 杭州微流汇科技有限公司 一种自催化氰源一锅法制备芳基伯酰胺的方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5633002A (en) 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
JP3471122B2 (ja) 1995-04-26 2003-11-25 アルケア株式会社 医療用粘着配合物
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
JP2001519787A (ja) 1997-04-03 2001-10-23 ポイント バイオメディカル コーポレイション 膀胱内ドラッグデリバリーシステム
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
AU9682801A (en) 2000-10-13 2002-04-22 Alza Corp Apparatus and method for piercing skin with microprotrusions
ATE428466T1 (de) 2000-10-26 2009-05-15 Alza Corp Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
PT2060259E (pt) 2001-11-01 2010-04-26 Spectrum Pharmaceuticals Inc Composições médicas para o tratamento intravesical do cancro da bexiga
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
ES2665999T3 (es) 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
JP2008520331A (ja) 2004-11-18 2008-06-19 トランスファーマ メディカル リミテッド 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ
US20070039624A1 (en) * 2005-08-18 2007-02-22 Roberts Richard H Patient compliance system and method to promote patient compliance
JP2007055940A (ja) * 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
EP2352544A4 (en) 2008-11-07 2013-12-25 Combinent Biomedical Systems Inc DEVICES AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF DISEASES
US20110046600A1 (en) 2008-12-05 2011-02-24 Crank Justin M Devices, systems, and related methods for delivery of fluid to tissue
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN103492389B (zh) * 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
PL3381917T3 (pl) * 2013-01-31 2021-12-27 Bellus Health Cough Inc. Związki imidazopirydynowe i i ch zastosowania
AU2014365823B2 (en) 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
CZ307147B6 (cs) * 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
WO2018064135A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Also Published As

Publication number Publication date
AU2017335674A1 (en) 2019-04-18
MX2019003710A (es) 2019-06-24
TW201827432A (zh) 2018-08-01
CN116854693A (zh) 2023-10-10
US20190092778A1 (en) 2019-03-28
US11339169B2 (en) 2022-05-24
US10174039B2 (en) 2019-01-08
IL265648A (en) 2019-05-30
US20220227774A1 (en) 2022-07-21
AR109776A1 (es) 2019-01-23
US20180093991A1 (en) 2018-04-05
EP3528813A4 (en) 2020-06-03
CN109996546A (zh) 2019-07-09
US20200190096A1 (en) 2020-06-18
CN109996546B (zh) 2023-06-27
KR20190053963A (ko) 2019-05-20
WO2018064135A1 (en) 2018-04-05
MX2022009736A (es) 2022-09-05
US10611768B2 (en) 2020-04-07
RU2019112740A (ru) 2020-11-02
EP3528813A1 (en) 2019-08-28
CA3037748A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
BR112019006216A2 (pt) compostos de p2x3 e/ou p2x2/3 e métodos
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201800367A1 (ru) Способы лечения болезни хантингтона
BR112016024472A8 (pt) composto, medicamento, e, uso de um composto
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
BR112016005271A2 (pt) Moduladores de canais de sódio para o tratamento da dor e do diabetes
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112022000377A2 (pt) Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
BR112012033566A2 (pt) dispositivo e métodos para o tratamento de uma patologia de articulação do membro inferior e dor do membro inferior
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
BR112013020874A2 (pt) composto, regime, método para a preparação do referido composto, e, uso de um composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]